US Patent

US11166947 — Effective dosing of a child for the treatment of ADHD with methylphenidate

Method of Use · Assigned to Neos Therapeutics LP · Expires 2038-01-25 · 12y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of treating ADHD in children by providing an effective amount of methylphenidate.

USPTO Abstract

The present invention generally relates to treating attention-deficit disorders (e.g., ADHD) by providing an effective amount of an ADHD-effective agent to a patient in need thereof (e.g., a child).

Drugs covered by this patent

Ritalin (methylphenidate) · Novartis

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3299`	—	Ritalin
`U-3299`	—	Ritalin
`U-3299`	—	Ritalin

Patent Metadata

Patent number: US11166947
Jurisdiction: US
Classification: Method of Use
Expires: 2038-01-25
Drug substance claim: No
Drug product claim: No
Assignee: Neos Therapeutics LP
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.